Should I Take NAD+? A Provider's Decision Path

Should I take NAD+? The evidence doesn't make NAD+ injections a first choice for tiredness or slowing aging. Dana is a fictional composite: 52, tired most afternoons, taking blood-pressure medicine and curious about NAD+.

A provider would follow these questions in order. The answer might involve more evaluation, another treatment, or deciding the uncertainty outweighs the reason to try it.

1. Should I take NAD+ for the goal I have?

NAD+ stands for nicotinamide adenine dinucleotide, a helper molecule cells use for energy and repair. NR, nicotinamide riboside, and NMN, nicotinamide mononucleotide, are precursors: ingredients the body uses to make NAD+. Swallowed NR or NMN and injected NAD+ are different treatment questions.

If Dana wants more energy, the provider first asks when the tiredness started, how she sleeps and what medicines she takes. Some blood-pressure medicines can contribute to tiredness. Thyroid problems and anemia, too few healthy red blood cells, are other possible causes (MedlinePlus's fatigue guide).

As of September 30, 2026, the day this article was written, a September 8 analysis offers a useful check on expectations. Gao and colleagues in Frontiers in Nutrition, 2026 pooled 16 studies with 1,126 people for reported tiredness. None of the tested NAD-related supplements showed a reliable improvement against placebo, a comparison treatment without the active ingredient. Those findings concern supplements, rather than NAD+ injections.

If Dana wants to slow aging, a higher blood result isn't enough. As of September 30, 2026, the day this article was written, Igarashi's September 25 trial in npj Aging, 2026 adds 24 weeks of follow-up. It assigned 62 adults aged 65 or older to oral NMN or placebo. Blood NAD+ rose without significant improvement in hearing or physical performance.

As of September 30, 2026, the day this article was written, Martens's July 21 trial in Alzheimer's & Dementia, 2026 provides a similar distinction for oral NR. Forty-two older adults with memory problems completed 12 weeks. Blood NAD+ roughly doubled, without clear improvement in memory or thinking.

Among 410 people with early Parkinson's disease, NOPARK's nicotinamide riboside results showed no symptom benefit despite higher blood NAD metabolism.

If Dana wants help with a specific condition, the people studied matter. Yoshino's 10-week Science trial, 2021 included 25 women after menopause, when menstrual periods have ended. They had overweight or obesity and prediabetes, blood sugar above normal but below the diabetes range. Oral NMN improved muscle response to insulin, the blood-sugar hormone, without improving blood sugar measured before eating.

That narrow finding doesn't establish a benefit from NAD+ injections for Dana's condition. The NAD+ myths guide checks the broader claims behind the interest.

2. Would an injection answer a different question?

Dana might assume that giving NAD+ directly must work better than a capsule. The human evidence hasn't established that shortcut. A study of one ingredient or delivery method cannot choose another method for her.

IV means delivery into a vein. In Grant's 2019 pilot in Frontiers in Aging Neuroscience, eight men received NAD+ over six hours; three received saline, saltwater. Researchers tracked blood and urine changes, rather than whether participants felt more energetic or aged more slowly.

That study cannot pick a schedule for an injection under the skin. The NAD+ injection overview explains the wider evidence. The prescriber sets any actual dose and schedule.

Promise offers NAD+ by prescription, after a licensed provider reviews your request; it is dispensed as a compounded injectable medication, meaning a pharmacy prepares it for a prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing.

A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

3. Does Dana's health history change the decision?

Pregnancy or breastfeeding would change this conversation. As of September 30, 2026, the day this article was written, the April 30 injection pilot remains a preprint, a report published before a journal's independent expert review. It excluded pregnancy and breastfeeding, so its results cannot establish safety for those groups. A provider may defer optional use when that evidence is missing.

Active cancer needs a separate discussion with the cancer-care team. As of September 30, 2026, the day this article was written, the researchers' April 1 announcement describes a Cancer Letters study of pancreas cancer in cells and mice. NAD+ precursors supported resistance to chemotherapy, medicines used to treat cancer. This was laboratory evidence about precursors, rather than proof of harm from NAD+ injections in people.

Dana's heart history, kidney or liver problems, allergies and complete medicine list also belong in the review. The small injection studies don't provide a reassuring answer for every health history.

4. Who prepares and monitors treatment?

The NAD+ IV death report also makes one practical question concrete for Dana: who is trained to place and monitor an IV line?

Preparation quality is another question. FDA's October 30, 2024 notice described severe chills, shaking, vomiting and fatigue after injectable NAD+, consistent with excessive endotoxin, bacterial residue that can trigger illness. The NAD+ side-effects guide covers reported reactions. A prescribed route adds a licensed clinician, a named pharmacy, a traceable lot and someone to contact.

5. Is NAD+ worth the expense and effort?

For Dana, worth depends on a specific goal and how much uncertainty she accepts. An ongoing expense is harder to justify when the only success measure is a blood number.

The practical conversation covers what the quoted service includes, follow-up, the prescribed schedule and who handles an unwanted effect. For any proposed IV, time at the clinic and monitoring are part of the commitment. Dana's work schedule matters alongside the medical questions.

A useful plan also names what would count as helpful, when it would be reviewed and what would prompt stopping. Continuing indefinitely because the biology sounds appealing isn't a clear plan. A provider may conclude that investigating the tiredness offers more value than adding treatment.

6. Would MOTS-c fit the goal better?

MOTS-c comes up in the same conversation because it is studied in mitochondria, the cell's energy-making parts. It is a peptide, a short chain of protein building blocks, studied as a signal. NAD+ is a helper molecule used in energy reactions.

That difference doesn't establish which would help Dana. In Reynolds's Nature Communications study, 2021, researchers measured naturally produced MOTS-c during exercise in 10 men. The treatment experiments were in mice. Those results cannot compare prescribed MOTS-c with NAD+ for her afternoon tiredness.

Adding both would add uncertainty, rather than supply the missing comparison. Either treatment remains a separate provider decision.

7. What would make the visit useful?

Dana's useful starting point is a description of the tiredness, her medicine and supplement list, relevant test results and her goal. The provider can then explain what existing care needs attention and whether NAD+ has a reasonable place in the discussion.

If treatment is considered, the conversation needs a follow-up date and a way to judge change. If the provider recommends more evaluation or another approach, that can be a useful answer. The aim is a decision Dana understands, with the provider accountable for follow-up.

At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.